Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Norbert Schmitz(University Hospital Münster), María Pascual(Universitat de València), David Valcárcel(Vall d'Hebron Hospital Universitari), Rodrigo Martino(Universitat Autònoma de Barcelona), Ana García‐Noblejas, D. Caballero(Complejo Hospitalario de Salamanca), Jorge Sierra(Universitat Autònoma de Barcelona), Juan Besalduch(Hospital Universitario Son Dureta), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Carmen Canals(Hospital de Sant Pau), Rafael F. Duarte(Institut Català d'Oncologia), Josep‐María Ribera(Universitat Autònoma de Barcelona), Mats Brune(Sahlgrenska University Hospital), Antonio Léon(Hospital Jerez Puerta del Sur), R. Arranz(Hospital Universitario de La Princesa), Jakob Passweg(University Hospital of Basel)
Cited by 215
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k